<DOC>
	<DOC>NCT02622659</DOC>
	<brief_summary>Randomized, double blind, double dummy, positive drug parallel comparison, multi-centre clinical trial to assess the efficacy and safety of Fuganlin Oral Liquid in children with influenza (acute upper respiratory infection).</brief_summary>
	<brief_title>The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)</brief_title>
	<detailed_description>Treatment group: Fuganlin Oral Liquid 10mL. Control group: Xiaoer Jiebiao oral liquid 100mL. Treatment for one week. Patients who were recovered within one week can withdrawal at any time.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>1. Patients diagnosed as acute upper respiratory infection. 2. Patients with Traditional Chinese Medicine syndrome of qi deficiency and windheat. 3. Patients aged 1 to 12 years. 4. With course of disease in 48 hours or less. 5. Signed informed consent by a Parent or legal guardians. 1. Patients diagnosed as tonsillitis, bronchitis, bronchiolitis, pneumonia; 2. Patients have a history of hyperpyretic convulsion; 3. Severe malnutrition, rickets patients and merge the heart, brain, liver, kidney and hematopoietic system and other serious primary diseases; 4. The increased of serum creatinine (Cr), blood urea nitrogen (BUN), alanine aminotransferase (ALT), and urinary protein, urine RBC above "+", which can not use the test illness or possibly combined disease conditions to explain; 5. Patients with allergic physique (Allergic to above two kinds of substance), allergic to the composition of the preparation or control drug; 6. According to the doctors' determination,likely to loss to follow up.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>acute upper respiratory infection</keyword>
</DOC>